# Digistain

Source: https://onco.cc/companies/digistain/  
OnCo record `digistain` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Digistain shines infrared light through a breast tumour slide and reads its chemical fingerprint to score how likely the cancer is to return, giving a result in a day rather than weeks and at a fraction of the cost of genomic tests.

## Summary

Digistain, an Imperial College London spin-out, measures the mid-infrared spectrum of a standard tumour section and applies an algorithm to produce a risk score for early breast cancer that is intended to guide chemotherapy decisions, an alternative to centralised genomic recurrence tests. The company cites a UK government-commissioned study showing clinical performance comparable to the market leader, and reports use with reimbursement at some cancer centres; it is supported by the NHS, YC and the European Investment Bank per its profile. Prospective outcome data are still limited.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- Tags: yc
- HQ: London
- Type: diagnostics
- Website: https://digistain.co.uk

## Sources

- Y Combinator profile: https://www.ycombinator.com/companies/digistain
- Official website: https://digistain.co.uk

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/)
- technologies: [Digital pathology & AI](https://onco.cc/technologies/digital-pathology-ai/), [Histopathology & immunohistochemistry](https://onco.cc/technologies/histopathology-ihc/)
- companies: [Y Combinator](https://onco.cc/companies/y-combinator/)

---
JSON: https://onco.cc/api/v1/entities/digistain.json